Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aggressive multiple sclerosis. Definition and specific therapeutic indication].

Gilles Edan1

  • 1Service de neurologie hôpital Pont de Chaillou rue Henri Le Guilloud 35033 Rennes.

Presse Medicale (Paris, France : 1983)
|March 19, 2004
PubMed
Summary

Mitoxantrone is the first immunosuppressor approved for aggressive multiple sclerosis (MS), significantly reducing relapses and disability progression. However, serious cardiac and hematological toxicities necessitate strict monitoring and limit its use to specialized neurology departments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Performances of experts and automated methods on new multiple sclerosis lesions detection: insights from the MSSeg2 challenge.

Scientific reports·2026
Same author

PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.

JAMIA open·2026
Same author

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Neurology·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a progressive neurological disease.
  • Aggressive MS is characterized by rapid disability accumulation, evidenced by frequent relapses or continuous EDSS score increase.
  • Mitoxantrone represents a novel immunosuppressive therapy for aggressive MS.

Purpose of the Study:

  • To evaluate the efficacy and safety of mitoxantrone in treating aggressive multiple sclerosis.
  • To define the criteria for aggressive MS and outline the benefits and risks of mitoxantrone therapy.

Main Methods:

  • Mitoxantrone (20 mg IV) administered in monthly cycles for 6 months.
  • Monitoring of relapse frequency, new MRI lesions, and disability progression (EDSS).
  • Strict echocardiographical monitoring for cardiac toxicity and regular blood counts for hematological toxicity.

Related Experiment Videos

Main Results:

  • Mitoxantrone significantly reduces relapse frequency in aggressive MS.
  • The treatment decreases the appearance of new lesions on MRI scans.
  • Mitoxantrone effectively slows the progression of disability in patients with aggressive MS.

Conclusions:

  • Mitoxantrone is an effective immunosuppressor for aggressive MS, offering significant benefits in disease control.
  • Potential severe side effects, including cardiac and hematological toxicity, require careful patient selection and rigorous monitoring.
  • The benefit-risk ratio must be thoroughly discussed with patients, with continued monitoring post-treatment.